Skip to content
DeepViews

Lantheus Holdings, Inc (LNTH) — 分析摘要

Lantheus Holdings, Inc(LNTH)的市值为6.58十亿美元,最近一年的营收同比增长了+0.5%。净利润率为15.2%。当前市盈率为23.9倍。

核心要点

  • 营收同比变化+0.5%
  • 净利润率15.2%
  • 市盈率23.9倍

与IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES板块的其他公司相比,LNTH的营收增长为+0.5%,市盈率为23.9倍。

[XNAS]

Lantheus Holdings, Inc (LNTH)

$100.77

更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR

市值
$6577.50M
企业价值
$6555.25M
市盈率
23.9
股息率
0.00%
EV/EBITDA
16.8
公司简介
关于
关于 Lantheus Holdings, Inc

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.

行业

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

员工人数

1,193

总部

NORTH BILLERICA, MA

Exchange

XNAS

官网
Source: Polygon.io
评分
竞争壁垒
竞争壁垒
71
宽护城河

基于 4 年财务数据的系统性竞争优势评估

此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。

市场信号
估值
盈利
内部人交易
内部人备案活动

首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。

加载 SEC 内部人备案数据...
超级投资者
财务健康
财务健康

资本结构

总权益$1311.78M
总债务$571.05M
债务权益比0.44
现金及等价物$593.30M

现金流

经营现金流$412.80M
自由现金流$387.83M
自由现金流率24.92%
P/FCF 比率16.96
Source: Polygon.io · SEC EDGAR
股息
最新资讯
Recent News

免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。